[go: up one dir, main page]

AU2001249310A1 - Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation - Google Patents

Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation

Info

Publication number
AU2001249310A1
AU2001249310A1 AU2001249310A AU4931001A AU2001249310A1 AU 2001249310 A1 AU2001249310 A1 AU 2001249310A1 AU 2001249310 A AU2001249310 A AU 2001249310A AU 4931001 A AU4931001 A AU 4931001A AU 2001249310 A1 AU2001249310 A1 AU 2001249310A1
Authority
AU
Australia
Prior art keywords
glycosylation
cell
beta
inhibitingpancreatic
protin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249310A
Inventor
Robert Konrad
Jeffrey Kudlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of AU2001249310A1 publication Critical patent/AU2001249310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001249310A 2000-03-21 2001-03-21 Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation Abandoned AU2001249310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19078500P 2000-03-21 2000-03-21
US60190785 2000-03-21
PCT/US2001/009010 WO2001070236A1 (en) 2000-03-21 2001-03-21 Preventing and/or treating diabetes mellitus

Publications (1)

Publication Number Publication Date
AU2001249310A1 true AU2001249310A1 (en) 2001-10-03

Family

ID=22702767

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249310A Abandoned AU2001249310A1 (en) 2000-03-21 2001-03-21 Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation

Country Status (3)

Country Link
US (1) US6589995B2 (en)
AU (1) AU2001249310A1 (en)
WO (1) WO2001070236A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186948A1 (en) * 2000-03-21 2003-10-02 Jeffrey Kudlow O-linked N-acetylglucosamine pathway in the pathogenesis of neurodegeneration and diabetes
CA2491763A1 (en) * 2005-01-06 2006-07-06 Tassos P. Anastassiades Blood glucose control with n-acylated glucosamines
ES2534465T3 (en) 2005-11-15 2015-04-23 Glycofi, Inc. Production of glycoproteins with reduced O-glycosylation
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
WO2008156676A1 (en) 2007-06-15 2008-12-24 President And Fellows Of Harvard College Methods and compositions for detecting and modulating o-glycosylation
CA2721459A1 (en) * 2008-05-20 2009-11-26 Merck Sharp & Dohme Corp. Efficient production of heterologous proteins using mannosyl transferase inhibitors
JP2011530311A (en) 2008-08-12 2011-12-22 グライコフィ， インコーポレイテッド Improved vectors and yeast strains for protein production: Ca2 + ATPase overexpression
JP2012528858A (en) 2009-06-01 2012-11-15 プレジデント アンド フェロウズ オブ ハーバード カレッジ O-GlcNAc transferase inhibitor and use thereof
WO2013006758A1 (en) 2011-07-06 2013-01-10 President And Fellows Of Harvard College Diphosphate mimetics and uses thereof
CN109044979B (en) * 2018-11-02 2020-12-25 江西省农业科学院 Sustained-release microspheres, protein glycosylation inhibitor sustained-release system, preparation and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1060174B1 (en) * 1997-12-23 2004-09-22 Amersham Health AS Nitric oxide releasing chelating agents and their therapeutic use
AU6378900A (en) * 1999-07-26 2001-02-13 Uab Research Foundation Protecting pancreatic beta-cells during islet isolation; assessing islet viability and candidate diabetes drugs after islet isolation

Also Published As

Publication number Publication date
US6589995B2 (en) 2003-07-08
US20020128235A1 (en) 2002-09-12
WO2001070236A8 (en) 2001-12-06
WO2001070236A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
GC0000258A (en) A genetically engineered bleb preparation for prevention or treatment of gram-negative bacterial disease
WO2003051389A3 (en) Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
AU2002349295A1 (en) Glucose dependant release of insulin from glucose sensing insulin derivatives
AU2001249310A1 (en) Prevention and/or treatment of diabetes mellitus by pharmacologically inhibitingpancreatic beta-cell o-linked protin glycosylation and/or pancreatic beta-cell p135 o-glycosylation
AU2002226633A1 (en) Treatment of diabetes mellitus using vardenafil
AU2002248304A1 (en) Vascular tissue composition
AU2000276362A1 (en) Composition for the treatment of diabetes
AU2001284413A1 (en) Medicinal compositions for preventing or treating heart failure
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU3025400A (en) Implantable actuating mechanism
AU5840200A (en) Treatment of diabetes and related pathologies
AU2002330095A1 (en) Flavonoids for treatment of diabetes
AU2000265109A1 (en) Method and compositions for prevention and/or treatment of diabetes and glucose modulation
AU2002356509A1 (en) Diagnosis of flavivirus infection
EP1532979A4 (en) Drug composition for blood sugar control
AU2432001A (en) Treatment of mental conditions including depression
AU2002215059A1 (en) Combination of amines and vanadium (IV)/(V) compounds for the treatment and/or prevention of diabetes mellitus
GB2355189B (en) Herbal preparation for the treatment of diabetes mellitus
AU2001257282A1 (en) Association of protein kinase c zeta polymorphisms with diabetes
AU2002359171A1 (en) Composition for the treatment of renal failure or gastric dysfunction of e.g. premature or neonatal mammals
AU2002357370A1 (en) Treatment for averting or delaying premature delivery
GB9926061D0 (en) Compositions for the treatment of diabetes mellitus
HK1064311A (en) Medicinal herbal compounds for the prevention and treatment of diabetes
AU2002237570A1 (en) Therapeutic and/or preventive agent for diabetic ischemic heart disease
AU2002258079A1 (en) Mechanism for prevention of premature activation, in particular in drug administration